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Background: As the long-term efficacy of stereotactic body radiation therapy (SBRT) becomes established and
other prostate cancer treatment approaches are refined and improved, examination of quality of life (QOL)
following prostate cancer treatment is critical in driving both patient and clinical treatment decisions. We present
the first study to compare QOL after SBRT and radical prostatectomy, with QOL assessed at approximately the same
times pre- and post-treatment and using the same validated QOL instrument.
Methods: Patients with clinically localized prostate cancer were treated with either radical prostatectomy
(n = 123 Spanish patients) or SBRT (n = 216 American patients). QOL was assessed using the Expanded Prostate
Cancer Index Composite (EPIC) grouped into urinary, sexual, and bowel domains. For comparison purposes, SBRT
EPIC data at baseline, 3 weeks, 5, 11, 24, and 36 months were compared to surgery data at baseline, 1, 6, 12, 24,
and 36 months. Differences in patient characteristics between the two groups were assessed using Chi-squared
tests for categorical variables and t-tests for continuous variables. Generalized estimating equation (GEE) models
were constructed for each EPIC scale to account for correlation among repeated measures and used to
assess the effect of treatment on QOL.
Results: The largest differences in QOL occurred in the first 1–6 months after treatment, with larger declines
following surgery in urinary and sexual QOL as compared to SBRT, and a larger decline in bowel QOL following
SBRT as compared to surgery. Long-term urinary and sexual QOL declines remained clinically significantly lower
for surgery patients but not for SBRT patients.
Conclusions: Overall, these results may have implications for patient and physician clinical decision making which
are often influenced by QOL. These differences in sexual, urinary and bowel QOL should be closely considered in
selecting the right treatment, especially in evaluating the value of non-invasive treatments, such as SBRT.
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The early-stage prostate cancer treatment landscape is
crowded with effective surgical and non-surgical treat-
ment options, yet, no randomized controlled trials to
date have proven the superiority of any one treatment
approach in terms of cancer control [1,2]. Technical
advances have added additional treatment options such* Correspondence: akatzmd@msn.com
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reproduction in any medium, provided the oras stereotactic body radiation therapy (SBRT) for which
several recent studies have shown promising biochem-
ical control [3-6]. Given this breadth of treatment
options the treatment decision process has become com-
plex, particularly for low-risk prostate cancer patients
where the prognosis is likely to be favorable independent
of which treatment they choose. Indeed, foregoing im-
mediate treatment and initiating active surveillance is an
increasingly attractive option for many patients [7]. Wilt
et al. [8] recently found in a randomized study that
neither all-cause nor prostate-cancer mortality were. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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prostatectomy or active surveillance, although prostatec-
tomy may reduce mortality in patients with higher PSA
scores or intermediate- and high-risk cancer. In this set-
ting, then, factors such as the invasiveness and length of
treatment, treatment-related toxicity, and the impact of
treatment on quality of life (QOL), play increasingly im-
portant roles in the treatment decision process.
The impact of treatment on prostate cancer patients’
QOL has been the focus of a variety of longitudinal
studies [9-14]. The instrument has been extensively vali-
dated [15] and applied successfully in Spanish-speaking
patients [9,16]. Most recently, Pardo et al. published a
longitudinal, comparative QOL study using the validated
Expanded Prostate Cancer Index Composite (EPIC)
QOL instrument for patients receiving surgery, external-
beam radiation therapy or brachytherapy but who did
not receive hormonal therapy [16]. Consistent with other
findings, this study demonstrated radical prostatectomy
was associated with urinary incontinence and sexual dys-
function whereas the radiation treatments were asso-
ciated with short-term decrements in bowel QOL and
gradual sexual QOL declines.
SBRT is a rapid, non-invasive treatment that precisely
delivers radiation to the moving prostate while limiting ra-
diation to surrounding normal tissues thereby offering the
potential for minimal toxicities while maintaining patient
QOL [17]. Whereas traditional radiation therapy imposes a
8–9 week treatment duration, SBRT has a one week treat-
ment duration that is comparable to radical prostatectomy,
but without being invasive. SBRT efficacy may also be com-
parable to radical prostatectomy; recent 5-year biochemical
disease-free survival rates of 93% have been reported [3].
Given the absence of any QOL comparison to date between
radical prostatectomy and SBRT, we sought to compare
QOL for SBRTand radical prostatectomy.Methods
Study design and participants
This was a retrospective study of clinically localized
prostate cancer patients treated with either radical pros-
tatectomy or SBRT. Radical prostatectomy patients were
participants in the Spanish Multicentric Study of Clinic-
ally Localized Prostate Cancer from April 2003 to March
2005. Details of the study are described elsewhere [9].
Briefly, the patients had stage T1 or T2 prostate cancer,
no previous transurethral prostate resection, and were
treated at one of 10 Spanish hospitals. For the purpose
of this analysis, only patients who received surgery and
who did not receive neoadjuvant or adjuvant hormonal
therapy were included. The patients underwent radical
retropubic prostatectomy with nerve-sparing at the sur-
geon’s discretion. Research protocols were approved bythe ethics review boards of each hospital and informed
written consent was obtained for all patients.
SBRT patients were selected from a larger group of
304 patients treated at Winthrop University Hospital
(Mineola, NY) from April 2006 to July 2008. The
patients included in the present study were only those
treated at least 3 years prior to analysis and not treated
with hormones. In addition, 31 patients from the larger
group were lost to follow-up or were dead of other
causes and were not included here. All patients signed
consent statements and were informed of the potential
risks involved with this treatment. Institutional IRB-
approval was obtained on the treatment protocol. Details
of the treatment are described elsewhere [5]. Briefly,
SBRT was delivered to patients with clinical stage T1c or
T2b prostate cancer using the CyberKnife (Accuray Inc.,
Sunnyvale, CA). Inverse treatment planning was per-
formed using a CT scan (1.5-mm cuts), with MRI fusion
where feasible two weeks after fiducial placement. All
pretreatment imaging was performed with the patient in
the same position used for treatment delivery. Changes
in the position of the prostate during treatment were
tracked and automatically corrected for with the aid of
gold fiducial markers implanted within the prostate. The
first 38 patients received a total dose of 35 Gy delivered
in 5 daily fractions; the remaining patients received a
total dose of 36.25 Gy in 5 daily fractions. The dose was
prescribed to a planning target volume (PTV) created by
a 5-mm expansion of the prostate gross tumor volume
(GTV), with a 3-mm posterior expansion. For intermediate-
and high-risk patients, the seminal vesicles were included in
the GTV. For high-risk patients, an 8-mm margin was added
on the involved side. All patients had the bladder, prostate,
rectum, seminal vesicles and penile bulb contoured, but the
urethra was not identified. On each treatment day patients
received 1500 mg of amifostine (MedImmune, LLC
Gaithersburg, MD) mixed in saline instilled into the rectum
[18,19]. As in the prostatectomy group, patients receiving
hormonal therapy were excluded.
Quality of life measure
At baseline, patient’s age, T stage, prostate-specific anti-
gen (PSA) level, Gleason histological grading scores,
prostate volume, and QOL were assessed. Patient risk
was assigned using the D’Amico et al. [1] definition of
risk. For the surgery patients, QOL assessment was
administered centrally by telephone interviews before
and 1, 3, 6, 12, 24, and 36 months after treatment. For
the SBRT patients, QOL assessment was administered in
person at baseline and either in person or by telephone
at 3 weeks, 5, 11, 24, and 36 months. QOL was assessed
using the Expanded Prostate Cancer Index Composite
(EPIC) [15]. The EPIC instrument (50 items) was con-
structed by expanding the University of California-Los
Table 1 Patient characteristics for the SBRT and surgery
cohorts
Patient characteristics SBRT Surgery p*
Number of Patients 216 123
Age (years) < 0.0001
Median 69.25 64.91
min 43.83 44.76
max 89.29 74.82
Age Group < 0.0001
< 60 34 (15.7%) 25 (20.3%)
60–69 88 (40.7%) 77 (62.6%)
>70 94 (43.5%) 21 (17.1%)
PSA (ng/ml) < 0.0001
mean 6.13 7.96
median 5.37 7.40
min 0.74 3.80
max 20.50 22.60
group < 0.0001
< 4 32 (14.8%) 2 (1.6%)
4–10 165 (76.4%) 94 (76.4%)
> 10 19 (%) 27 (22.0%)
Gleason p = 0.0050
<7 162 (75.0%) 71 (57.7%)
7 52 (24.1%) 48 (39.0%)
>7 2 (0.9%) 3 (2.4%)
unknown 0 (0.0%) 1 (0.8%)
T Stage < 0.0001
T1 191 (88.4%) 82 (66.7%)
T2 25 (11.6%) 41 (33.3%)
Risk < 0.0001
Low 156 (72.2%) 52 (42.3%)
Intermediate 56 (25.9%) 67 (54.5%)
High 4 (1.9%) 4 (3.3%)
Prostate Volume (cc)† p = 0.005
median 57.30 52.41
min 16.8 12.0
max 224.0 152.0
†The prostate volume was unknown for 20 surgery patients.
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bother in the four domains (urinary, bowel, sexual, and
hormonal). All EPIC items are answered on a 5-point
Likert scale. For each domain a summary score were
constructed as recommended by the developers of the
questionnaire. EPIC scores range from 0 to 100 with
higher scores reflecting better QOL. For comparison
purposes, SBRT EPIC data at 3 weeks, 5, 11, 24, and
36 months were compared to surgery data at 1, 6, 12,
24, and 36 months. The Spanish version of the EPIC
administered to the surgery patients has shown equiva-
lence with the original version [20].
Statistical analysis
Differences in patient characteristics between the two
patient populations were assessed using Chi-squared
tests for categorical variables and t-tests for continuous
variables. Differences in baseline QOL scores were
assessed using t-tests. Statistical significance was estab-
lished at α = 0.05, and changes in QOL that exceeded
half a standard deviation from the baseline value were
defined as clinically significant [21]. Generalized estimat-
ing equation (GEE) models were constructed for each
EPIC scale to account for correlation among repeated
measures and used to assess the effect of treatment on
QOL. The GEE models included baseline patient age as
a continuous variable, risk group as a categorical vari-
able, and prostate volume as a continuous variable as
adjusting factors. Variables included in the model were
chosen because their clinical significance is clear in prac-
tice and in the literature on prostate cancer treatment,
and they were statistically significant in the bivariate
analyses. Time was included as a categorical variable in
the model using the baseline, 1, 6, 12, 24 and 36 month
time points. Surgery was used as the reference group in
these GEE models. GEE allows the presence of missing
values in the repeated measurements of the dependent
variable, without having to exclude individuals with in-
complete data and with no need of imputation methods
(even though missing completely at random does not
hold) [22]. The GEE statistical analyses were carried out
using SAS 9.3 software, all other analyses were carried
out using GraphPad Prism 5.04.
Results
A total of 216 SBRT patients and 123 surgery patients
were included in this analysis. As summarized in Table 1,
the patient characteristics were significantly different be-
tween treatment groups for age, baseline PSA, Gleason
score, T Stage, risk and prostate volume. Overall the
SBRT patients were older, with lower baseline PSA
values. In addition, more of the SBRT patients had low-
risk disease and their prostate volumes were larger. Fur-
thermore, the use of medications for erectile functiondiffered between the two patient populations. A small
percentage of the SBRT patients retained sexual function
with the use of medications such as Sildenafil whereas
fewer of the surgery patients used such aids.
Table 2 compares baseline EPIC QOL between the two
patient populations. Baseline EPIC urinary QOL was sig-
nificantly different with the SBRT patients having lower
baseline urinary QOL. Sexual QOL was significantly dif-
ferent between the SBRT patients and all surgery
Table 2 Baseline EPIC Quality of life scores
Quality of life scores SBRT Surgery p*
Urinary < 0.0001
Mean 89.27 95.25
SD 8.34 12.27
Sexual 0.0400
Mean 57.78 52.57
SD 22.34 22.29
Nerve-Sparing 0.6920
Mean 57.78 59.41
SD 22.34 16.30
Non-Nerve-Sparing 0.0079
Mean 57.78 50.17
SD 22.34 23.65
Bowel 0.1441
Mean 95.47 96.43
SD 6.05 5.33
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line. Comparison of baseline sexual QOL between the
SBRT patients and the patients for whom a nerve-
sparing surgical procedure was used, however, showed
no significant difference. Baseline bowel QOL was com-
parable between the two treatment groups.
Mean EPIC QOL scores over time for the SBRT and
surgery patients are shown in Figure 1. Mean urinary
scores for surgery patients exhibited a clinically signifi-
cant decline at 1 month-post treatment, improved at 6
and 12 months, but remained clinically significantly
lower than at baseline at all follow-up times. Mean urin-
ary scores for SBRT patients also exhibited a clinically
significant decline at 1 month post-treatment. The mean
urinary score for SBRT patients improved by 6 months
and was no longer clinically significantly different at all
subsequent follow-up times.
Given the differences in baseline EPIC QOL scores for
surgery patients receiving nerve-sparing and non-nerve-
sparing procedures the EPIC surgery QOL scores were
examined as two separate groups: nerve-sparing and
non-nerve-sparing. Independent of surgical approach, all
surgery patients experienced a clinically significant de-
cline in EPIC sexual QOL at 1 month. At 6 months,
patients receiving non-nerve-sparing surgery retained
clinically significantly lower sexual QOL with only mod-
est improvements by 36 months. Patients receiving
nerve-sparing surgery also retained clinically signifi-
cantly lower sexual QOL than baseline but had improve-
ments at 6 months compared to 3 months. For SBRT
patients, the mean sexual QOL declined at 1 month with
subsequent return to near baseline sexual QOL by12 months. At no point was the decline in mean EPIC
sexual QOL clinically significant for the SBRT patients.
Mean bowel QOL scores for surgery patients exhibited
a small, but clinically significant decline at 1 month fol-
lowed by recovery to near baseline by 6 months. For
SBRT patients, the mean bowel scores exhibited a clinic-
ally significant decline at one month that improved by
6 months. The mean bowel scores for SBRT patients
remained clinically significantly lower than baseline until
12 months after which they were no longer clinically sig-
nificantly different from baseline.
Table 3 summarizes the results from the GEE models
to assess impact at different follow-up times. For the
urinary model, patients receiving SBRT had significantly
higher QOL throughout follow-up with the largest dif-
ference at one month. For the sexual model comparison
of SBRT to all surgery patients, surgery patients had sig-
nificantly lower sexual QOL at all time points. For the
bowel model, the most significant difference occurs at
1 month where surgery patients had significantly higher
QOL.
Discussion
As the long-term efficacy of SBRT becomes established
and other prostate cancer treatment approaches are
refined and improved, continued research into QOL
after prostate cancer treatment is critical in driving both
patient and clinical treatment decisions. Indeed, 5-year
follow-up for SBRT has yielded disease control that
approximates that produced by surgery and other con-
ventionally fractionated radiation therapy treatments [3].
Thus, preservation of QOL may become the primary
basis upon which patients choose a prostate cancer
treatment. It is in this context that we present the first
study to compare QOL after SBRT and radical prostatec-
tomy, with QOL assessed at approximately the same
times pre- and post-treatment and using the same vali-
dated QOL instrument (EPIC). In this study, the largest
differences in QOL occurred in the first 1–6 months
after treatment, demonstrating larger declines following
surgery in urinary and sexual QOL as compared to
SBRT, and a larger decline in bowel QOL following
SBRT as compared to surgery. Overall, these results may
have implications for patient and physician clinical deci-
sion making which are often influenced by QOL.
Urinary and sexual function are the primary concerns
for men undergoing prostate cancer treatment [9,14,16].
Urinary QOL is typically altered by several types of urin-
ary complications. Incontinence, leakage of urine, is the
predominant urinary issue after surgery [14,16] with
3 month continence rates of 51-74% for radical prosta-
tectomy [23-25] that improve to 80-94% by 12 months
[23,26]. Incontinence is not typically a concern following
SBRT [4,5,27,28], more typical are urinary toxicities such
Figure 1 Unadjusted mean EPIC quality of life scores plotted
over time for (A) urinary, (B) sexual, and (C) bowel quality of
life. The SBRT patient scores are shown with a dashed line and the
surgery patients are shown with a solid line. EPIC domain scores
range from 0 to 100 with higher values indicating higher quality of
life. For the sexual domain, the surgery scores are divided into those
patients receiving the nerve-sparing (solid line) and non-nerve-
sparing (dotted line) techniques. Asterisks (*) denote time points at
which scores were clinically significantly different from baseline.
Error bars denote 95% confidence intervals.
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10% [3-5,27-29]. A major urinary factor in surgery is that
the urethra is cut in half during surgical removal of the
prostate and then reconnected during the surgery,
whereas the urethra remains completely intact and is
identified and avoided during SBRT. As a result surgery
patients require a catheter that stays in place following
discharge from the hospital for 7 to 10 days after treat-
ment and often patients must use pads to address urine
leakage in the months following treatment. In this ana-
lysis, the overall EPIC urinary domain was analyzed, but
the EPIC urinary sub-domain scores for incontinence
and obstruction were not analyzed. For the SBRT
patients, only the overall urinary summary score for each
patient was recorded which prevented analysis of the
sub-domain scores in this analysis. A prior examination
of this EPIC surgery data using the obstruction and in-
continence sub-domains showed urinary obstructive
QOL had a transient decline at one month followed by
return to baseline with even improvement for patients
with preexisting urinary irritative-obstructive symp-
toms, whereas urinary incontinence QOL significantly
impacted surgery patients at all time points [16].
In the current study, SBRT patients had significantly
higher sexual QOL after treatment than surgery patients
with no clinically significant decline in sexual QOL at
any of the study’s follow-up time points. In contrast, the
surgery patients, whether or not the nerve-sparing tech-
nique was used, had clinically significant declines in sex-
ual QOL at all time points. This is not surprising given
the difficulty in identifying the neurovascular bundle in
the operating room and the mechanical and thermal in-
jury that may occur to the nerves during surgery. While
robotic assisted laparoscopic prostatectomy is more
commonly used in the United States, the surgical
patients in this study received open radical retropubic
prostatectomy, as laparoscopic surgery was not routinely
offered in the Spanish hospitals at the time of their
study. It remains unknown how significant of an impact
laparoscopic (either robotic or not) has on sexual QOL
as published functional outcomes vary greatly. For ex-
ample, potency rates at 12 months for robotic-assisted
laparoscopic prostatectomy range from 61–97% [30-34]
with patient selection, potency definition, surgeon
Table 3 Generalized estimating equation models of the association between EPIC scores surgery and SBRT patients
Variable EPIC urinary EPIC sexual EPIC bowel
β SE p β SE p β SE p
Intercept 98.9668 4.7493 <.0001 133.2671 9.3670 <.0001 103.1127 2.8919 <.0001
Age −0.0358 0.0695 0.6062 −1.2686 0.1368 <.0001 −0.0954 0.0435 0.0282
Prostate Volume −0.0209 0.0227 0.3557 −0.0014 0.0382 0.9702 −0.0158 0.0121 0.1927
Risk Group
Low Ref. Ref. Ref.
Intermediate-high 0.7602 1.1711 0.5163 1.2493 2.0884 0.5497 0.6897 0.5534 0.2127
Treatment Group (differences at baseline)
Surgery Ref. Ref. Ref.
SBRT −6.1083 1.1334 <.0001 11.1251 2.6339 <.0001 −0.2676 0.6838 0.6956
Interaction surgery x time (change from baseline)
Baseline Ref. Ref. Ref.
1 month −48.5886 3.3500 <.0001 −38.7584 2.7183 <.0001 −2.4796 1.1901 0.0372
6 months −19.2903 2.1428 <.0001 −34.6929 2.2146 <.0001 −0.2362 0.8788 0.7881
12 months −13.3859 1.8891 <.0001 −29.6338 2.2676 <.0001 1.1840 0.7165 0.0984
24 months −14.1136 1.8888 <.0001 −30.1501 2.5436 <.0001 1.4723 0.6095 0.0157
36 months −12.8108 1.6371 <.0001 −27.3960 2.4127 <.0001 2.6794 0.5251 <.0001
Interaction SBRT x time (differences from surgery in change from baseline)
Baseline Ref. Ref. Ref.
1 month 32.8134 3.3992 <.0001 31.3269 2.8315 <.0001 −18.7600 1.4602 <.0001
6 months 17.8838 2.4335 <.0001 30.6081 2.6451 <.0001 −3.5163 1.4358 0.0143
12 months 11.4988 1.9338 <.0001 26.2387 2.3241 <.0001 −2.6986 1.0348 0.0091
24 months 13.3402 1.9474 <.0001 24.6944 2.6305 <.0001 −1.8731 0.9630 0.0518
36 months 13.6449 1.6969 <.0001 19.8132 2.5509 <.0001 −2.5845 0.6613 <.0001
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accounting for the large variation in rates [33]. Indeed, a
recent review by Finkelstein et al. at NYU in which they
examine multiple comparative publications states “it is
difficult to determine if one approach is superior to the
other for the preservation of neurovascular bundles and
sexual function” [35].
Baseline mean EPIC sexual QOL scores for the
patients receiving SBRT and nerve-sparing surgery in the
current study were similar whereas the patients receiving
non-nerve-sparing surgery had significantly lower base-
line mean EPIC sexual QOL scores. This low baseline
sexual QOL likely reflects why these patients were not
chosen for the nerve-sparing procedure in that their sex-
ual function was already grossly impaired. Mean EPIC
sexual scores were observed to drop dramatically in the
short term after surgery independent of surgical ap-
proach. While patients receiving nerve-sparing surgery
had a greater degree of recovery neither group recovered
back to baseline levels. In contrast, mean EPIC scores
after SBRT declined slowly over time but were not clin-
ically significantly different than the baseline levels.Failure to return to baseline sexual function is not un-
common following prostatectomy. Levinson et al., found
27% of 568 patients receiving laparoscopic radical pros-
tatectomy returned to baseline EPIC sexual QOL at
24 months [36]. Similarly, while in a study of potent
patients Willis et al. observe a greater return to baseline
function for patients receiving robotic-assisted laparo-
scopic prostatectomy the mean EPIC sexual QOL score
at 12 months remained 66.2 and 73.7% of the baseline
score for robotic-assisted laparoscopic prostatectomy
and laparoscopic prostatectomy, respectively [37].
Wiegner and King at Stanford University assessed sex-
ual QOL using EPIC for 32 low-risk prostate cancer
patients who received SBRT (36.25 Gy in 5 fractions)
[38]. The mean baseline sexual QOL score of 67.5
declined to 56.4, 50.7 and 37.4 at 12, 20 and 50 months,
respectively. McBride et al. report sexual QOL using
EPIC for 26 patients treated with SBRT (primarily 35 or
36.26 Gy in 5 fractions) as part of a multi-institutional
study [29]. The median baseline sexual QOL score of 43
declined to 17 at 36 months. The small number of
patients in both of these studies may reflect upon the
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also consisted of patients treated very early in the
groups’ SBRT experience and prior to adoption of more
advanced and currently used SBRT techniques, such as
advanced collimation that have been shown to spare
more normal tissue during treatment [39,40]. In addition,
the Stanford report did not incorporate the use of MRI
which is routinely used to definitively identify the neuro-
vascular bundles in treatment planning.
Mild to moderate bowel toxicity consisting of proctitis
and rectal bleeding has been reported following SBRT
[4,29,41]. In contrast, very low rates of bowel injury
have been reported during prostatectomy [42,43], as
bowel complications are not typically an issue for
patients undergoing surgery. In the current study, bowel
QOL was minimally affected by surgery whereas bowel
QOL fell after SBRT but returned to near baseline 6–
12 months post-treatment. This is consistent with studies
showing the incidence of Grades 2 and 3 bowel toxicity
after SBRT (as measured using the RTOG scale) range
from 4–24% in the acute phase, but falls to 1-12% in the
late phase [4,5,28,29,41,44-46].
The present study is limited by the retrospective na-
ture of the analysis despite the prospective data collec-
tion for the two treatment groups. First, treatment
groups differed at baseline in ways that might be
expected of such a retrospective analysis, and which
might have contributed to post-treatment differences be-
tween groups. SBRT patients were older, on average,
than surgery patients. Although the influence of age was
considered by including it in the GEE models, adjusting
for age is not sufficient since we do not have data for
surgery patients older than 74 years. Differences in the
use of treatment for erectile dysfunction may affect sex-
ual outcomes; for example, baseline sexual scores of the
older patients in the SBRT group were as good or better
than the surgery patients, suggesting a possible relation-
ship with higher sildenafil intake among SBRT patients.
However, this could not be included as a baseline adjust-
ment because patients started sildenafil use at various
timepoints throughout the study. Other lifestyle factors
such as smoking, marital status, and education, and
comorbidities were not explicitly balanced between
groups so their contribution cannot be assessed. General
QOL at baseline was also not assessed. Second, nerve-
sparing techniques were not widely applied in the sur-
gery group (28% of patients treated with prostatectomy),
and therefore, our findings from the GEE model for the
prostatectomy group as a whole could overestimate their
adverse sexual effects. Third, both the SBRT and surgery
groups had small numbers of patient responses early in
their studies. For the surgery patients, the 1-month fol-
low-up had the fewest responses whereas for the SBRT
group the 6 month follow-up had the fewest. For thesexual domain, GEE analysis excluding the 1- and 6-
month time points showed similar results, suggesting
these fluctuations in questionnaire completion did not
greatly impact the results. Fourth, there are QOL
domains that are not assessed by EPIC which may differ
between groups, e.g., fatigue and general quality of life.
A more extensive analysis of a broader range of QOL
variables may permit more complete comparisons. Some
aspects of treatment could not be rigorously controlled,
including surgeon expertise which is known to affect
disease-control and toxicity outcomes. These issues of
heterogeneity across groups could only be addressed ef-
fectively in the context of a randomized design. Finally,
prostate treatment is an evolving practice; results such
as these are based on a limited snapshot of current prac-
tices. The emphasis on QOL in prostate cancer patients
demands continuing re-analyses of QOL outcomes as
treatments evolve.
Conclusions
This is the first study to examine comparative QOL after
SBRT and radical prostatectomy for which differences in
QOL occurred immediately following treatment after
which relevant, but less substantial differences remained
for up to 3 years. These differences in sexual, urinary
and bowel QOL should be closely considered in select-
ing the right treatment for patients and important fac-
tors in the overall treatment decision process, especially
in evaluating the value of non-invasive treatments, such
as SBRT. SBRT had a greater impact on short-term
bowel QOL than surgery but had clinically significant
advantages in preserving urinary and sexual QOL as
compared to surgery. Long-term urinary and sexual
QOL declines remained clinically significantly lower for
surgery patients but not for SBRT patients. While add-
itional research is needed to understand how different
surgical approaches may impact QOL, incontinence and
sexual dysfunction remain the primary concern for sur-
gery patients. In particular for low-risk patients who
may reasonably be considered for active surveillance,
preservation of QOL may become the primary basis for
choosing a prostate cancer treatment.
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